CATX · Perspective Therapeutics Inc
United States · RS rating 3 · As of 2026-11-03
| Price | 0.88 USD |
|---|---|
| 1-day change | -15.4% |
| RS rating (overall / 1M / 3M / 12M) | 3 / 2 / 4 / 13 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 2 / 27 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | +12.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +84.4% |
| Market cap (USD) | $514.2M |